MMP2 and neoplasm: Taking this into account, Bjorklund et al. [211], in a pioneering study, developed an inhibitory peptide (ADGACIL WMDDGWCGAAG) that binds selectively to the MMP9 PEX domain and prevents PEX from binding to αvβ5 integrin; consequently, this peptide prevents tumour xenograft growth in vivo [211].